French drug company Sanofi announced it's discontinuing research and development for its next-generation mRNA flu vaccine.

A new nasal spray vaccine for H5N1 bird flu has shown promising early results, raising hopes it could one day be used to help ...

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

UVA Health researchers are advancing a technology that may allow new vaccines to be designed, tested and distributed in weeks ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

By Hugo Francisco de Souza Inside the rigorous, step-by-step process the CDC uses to create pandemic-ready flu vaccine ...

VANCOUVER, BC, CANADA, January 15, 2026 / EINPresswire.com / — Eyam Health and iiDiagnostics (iiDX), a company formed by the ...

Pfizer (NYSE:PFE) agreed to acquire weight loss drug developer Metsera for US$10b, entering the obesity and GLP-1 market. The ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Recent reports of Nipah virus (NiV) infections in West Bengal, India, have reignited global concern, prompting public health ...

Chelsea Cirruzzo is a Washington correspondent at STAT, where she covers HHS. You can reach Chelsea on Signal at chelseacirruzzo.42. Helen Branswell covers issues broadly related to infectious ...